Sensei Biotherapeutics (NASDAQ:FTH) Shares Climb 8.7% – Here’s What Happened

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) traded up 8.7% during mid-day trading on Tuesday. The company traded as high as $20.70 and last traded at $21.1350. 126,876 shares were traded during mid-day trading, a decline of 48% from the average daily volume of 244,265 shares. The stock had previously closed at $19.44.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 26th. Oppenheimer initiated coverage on Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 target price on the stock. JonesTrading began coverage on Sensei Biotherapeutics in a report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 price objective on the stock. Robert W. Baird started coverage on Sensei Biotherapeutics in a research report on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price for the company. Finally, Raymond James Financial began coverage on Sensei Biotherapeutics in a research note on Friday, July 31st. They set an “outperform” rating and a $56.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $56.25.

Sensei Biotherapeutics Price Performance

The business’s 50 day moving average is $31.21. The firm has a market capitalization of $540.26 million, a PE ratio of -0.15 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($5.04) by $2.20. Research analysts forecast that Sensei Biotherapeutics, Inc. will post -13.69 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Citadel Advisors LLC purchased a new stake in shares of Sensei Biotherapeutics in the 2nd quarter worth $307,000. Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics during the second quarter worth $3,610,000. Vivo Capital LLC purchased a new stake in Sensei Biotherapeutics in the first quarter valued at approximately $22,758,000. Bank of America Corp DE increased its holdings in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the last quarter. Finally, Stempoint Capital LP purchased a new position in Sensei Biotherapeutics during the first quarter worth about $4,188,000. 10.50% of the stock is owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.